MOTS-c vs 5-Amino-1MQ: A Research Comparison Guide
MOTS-c and 5-Amino-1MQ are frequently grouped together in discussions of metabolic research compounds, and searches often pair them because both are studied for effects on fat metabolism, insulin sensitivity, and energy balance. In practice, though, they sit in almost completely different molecular categories: one is a small peptide encoded by mitochondrial DNA, and the other is a synthetic small-molecule enzyme inhibitor. They reach metabolism through unrelated mechanisms.
This comparison is written for researchers and curious readers trying to understand how the two compounds actually differ in chemistry, mechanism, and evidence. It is not a recommendation to use either one; both are investigational, and most of what is known comes from cell-culture and rodent studies rather than controlled human trials.
Research-only notice: MOTS-c and 5-Amino-1MQ are research compounds. Neither is approved by the FDA (or comparable regulators) for the treatment, prevention, or diagnosis of any condition, and neither has an established human safety profile. Nothing here is medical advice, a dosing protocol, or an endorsement. The material is provided strictly for educational and scientific-literacy purposes.
| Feature | MOTS-c | 5-Amino-1MQ |
|---|---|---|
| Class / type | Mitochondrial-derived peptide (16 amino acids), encoded within the 12S rRNA region of mitochondrial DNA | Synthetic small molecule (5-amino-1-methylquinolinium), a quinolinium-based enzyme inhibitor |
| Mechanism | Activates AMPK via the folate–AICAR pathway; under stress translocates to the nucleus and engages NRF2/ARE-linked gene programs | Inhibits nicotinamide N-methyltransferase (NNMT), sparing intracellular NAD+ and S-adenosylmethionine (SAM) and lowering 1-methylnicotinamide |
| Half-life | Not established in humans; as a small peptide, expected to clear quickly (exercise-induced levels return toward baseline within hours) | Not established in humans; rodent/preclinical data suggest a half-life on the order of hours, with oral absorption |
| Regulatory status | Not approved for human use; investigational research compound | Not approved for human use; investigational research compound |
| Evidence level | Preclinical (cell + rodent), plus human observational/biomarker data on circulating levels; no completed efficacy trials | Preclinical only (cell culture + rodent); no registered human clinical trials |
| Primary research focus | Insulin sensitivity, exercise physiology, aging, skeletal-muscle and metabolic homeostasis | Adipocyte metabolism, diet-induced obesity, the NAD+/SAM axis |
Mechanism: two different levers on metabolism
MOTS-c is one of a small family of mitochondrial-derived peptides. It was identified by Lee and colleagues in 2015, who described a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Mechanistically, MOTS-c appears to act on the folate cycle, raising AICAR and thereby activating AMP-activated protein kinase (AMPK), a central cellular energy sensor. Downstream, this is associated with increased glucose uptake in skeletal muscle. Under metabolic stress, MOTS-c has also been reported to move into the nucleus and interact with antioxidant-response (ARE) transcription factors including NRF2, a form of mitochondria-to-nucleus retrograde signaling. Because AMPK activation broadly mimics several adaptations to exercise, MOTS-c is often described in the literature as an exercise-mimetic-like signal.
5-Amino-1MQ works on an entirely different node. It is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that uses SAM to methylate nicotinamide into 1-methylnicotinamide (MNA). That single reaction consumes two valuable pools at once: nicotinamide, a precursor for NAD+ salvage, and SAM, the cell’s main methyl donor. By occupying the NNMT active site, 5-Amino-1MQ slows that reaction, and in cultured adipocytes this has been associated with lower MNA, higher intracellular NAD+ and SAM, and suppressed lipogenesis. So where MOTS-c pushes a signaling kinase, 5-Amino-1MQ removes a metabolic drain by blocking an enzyme — different targets, different biochemistry.
Evidence and development status
Both compounds are early-stage, but their evidence bases have different shapes. The MOTS-c literature is broader and older. Beyond the founding 2015 metabolic work, MOTS-c has been studied as an exercise-induced regulator of age-related physical decline and muscle homeostasis (Reynolds and colleagues, 2021), and there is human observational data showing that circulating MOTS-c rises with exercise and tends to decline with age. That said, the human data are largely correlational or biomarker-level; there are no completed large-scale trials demonstrating that administering MOTS-c produces clinical benefit.
The 5-Amino-1MQ evidence base grows out of NNMT target validation. Kraus and colleagues (2014) showed in Nature that knocking down NNMT in fat and liver protected mice against diet-induced obesity by increasing energy expenditure, without changing food intake — establishing NNMT as a plausible metabolic target. Neelakantan and colleagues (2018) then reported that selective, membrane-permeable small-molecule NNMT inhibitors reduced body weight and white-adipose mass in diet-induced-obese mice, shrank adipocytes, and lowered plasma cholesterol. 5-Amino-1MQ belongs to that methylquinolinium chemical family. Importantly, this is rodent and cell-culture work; there are no registered human clinical trials of 5-Amino-1MQ and no published human safety or efficacy data.
Research context and delivery
A practical distinction that matters in the research setting is molecular form. MOTS-c is a peptide, which generally means it is not orally stable and is studied via injection in animal models; its pharmacokinetics in humans remain formally uncharacterized. 5-Amino-1MQ is a small molecule with reported oral absorption in preclinical work, which is part of why it is often discussed as an orally studied agent. Neither profile should be read as an endorsement of any route of administration in humans, because neither has been validated for human use. It is also worth being precise about naming: despite being catalogued on peptide-focused resources, 5-Amino-1MQ is not a peptide at all, whereas MOTS-c is a genuine endogenous peptide the body produces.
Key differences
- Molecule type: MOTS-c is a 16-amino-acid endogenous peptide; 5-Amino-1MQ is a fully synthetic small-molecule enzyme inhibitor.
- Target: MOTS-c activates the AMPK energy-sensing pathway; 5-Amino-1MQ inhibits the NNMT enzyme.
- Biochemical effect: MOTS-c drives exercise-like metabolic signaling; 5-Amino-1MQ conserves NAD+ and SAM by reducing their consumption.
- Endogenous vs foreign: MOTS-c occurs naturally and rises with exercise; 5-Amino-1MQ is a xenobiotic not found in the body.
- Evidence breadth: MOTS-c has broader literature spanning metabolism, aging, and muscle, including human biomarker data; 5-Amino-1MQ’s evidence is narrower and centered on adipose/obesity in animals and cells.
- Form and route: MOTS-c is a peptide studied by injection; 5-Amino-1MQ is a small molecule with preclinical oral absorption.
Which for what research?
Framed purely as research tools, the two suit different questions. Investigators interested in AMPK signaling, exercise-mimetic pathways, mitochondrial-to-nuclear communication, or age-related changes in muscle and glucose handling have historically reached for MOTS-c, because that is where its literature is deepest. Investigators focused on the NAD+/SAM axis, methyltransferase biology, adipocyte lipogenesis, or NNMT as an obesity target are the natural audience for 5-Amino-1MQ. The two are not interchangeable and are not competing versions of the same idea; they interrogate different parts of metabolism. Neither has the human trial data that would let anyone draw conclusions about effectiveness or safety in people, so any comparison remains one of research directions rather than proven outcomes. Put these side by side in the Compare Peptides tool.
Is 5-Amino-1MQ a peptide like MOTS-c?
No. MOTS-c is a genuine 16-amino-acid peptide encoded by mitochondrial DNA. 5-Amino-1MQ is a synthetic small molecule (a quinolinium compound) that inhibits an enzyme. They are often listed together, but only MOTS-c is a peptide.
Do they share a mechanism of action?
No. MOTS-c is associated with activation of the AMPK energy-sensing pathway via folate/AICAR signaling. 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), which spares NAD+ and S-adenosylmethionine. These are unrelated targets.
Has either been tested in humans?
Neither has completed rigorous human efficacy trials. MOTS-c has human observational and biomarker data (circulating levels change with exercise and age), while 5-Amino-1MQ has no registered human clinical trials and no published human safety or efficacy data. Both remain preclinical or investigational.
What is known about their half-lives?
Human half-lives are not formally established for either. As a small peptide, MOTS-c is expected to clear quickly; 5-Amino-1MQ’s rodent data suggest a half-life on the order of hours. These preclinical figures should not guide human use.
Are they approved or legal for human use?
Neither is approved for human use by the FDA or comparable agencies. Both are handled as research compounds and carry no established human safety profile.
Sources
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PubMed 25738459
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PubMed 33397889
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PubMed 24717514
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PubMed 29155147
- Review: MOTS-c — a mitochondrial-derived peptide for therapeutic exploitation. PMC9905433